CN117466959A - 一种肝靶向化合物、缀合物及应用 - Google Patents
一种肝靶向化合物、缀合物及应用 Download PDFInfo
- Publication number
- CN117466959A CN117466959A CN202311424154.9A CN202311424154A CN117466959A CN 117466959 A CN117466959 A CN 117466959A CN 202311424154 A CN202311424154 A CN 202311424154A CN 117466959 A CN117466959 A CN 117466959A
- Authority
- CN
- China
- Prior art keywords
- compound
- liver
- targeting
- mmol
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 56
- 230000008685 targeting Effects 0.000 title claims abstract description 45
- 210000004185 liver Anatomy 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 claims abstract description 15
- 229930182830 galactose Natural products 0.000 claims abstract description 10
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 9
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims abstract description 8
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims abstract description 8
- 150000008275 galactosamines Chemical class 0.000 claims abstract description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- -1 bis (4-methoxyphenyl) phenylmethyl Chemical group 0.000 claims description 6
- 125000000524 functional group Chemical group 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 3
- 108091005461 Nucleic proteins Proteins 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 229940126586 small molecule drug Drugs 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 9
- 230000005764 inhibitory process Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 4
- 150000002772 monosaccharides Chemical class 0.000 abstract description 3
- 101150075175 Asgr1 gene Proteins 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 93
- 238000006243 chemical reaction Methods 0.000 description 38
- 239000000243 solution Substances 0.000 description 33
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 239000012074 organic phase Substances 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 24
- 238000003786 synthesis reaction Methods 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- 239000012071 phase Substances 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 108020004459 Small interfering RNA Proteins 0.000 description 10
- 108020004999 messenger RNA Chemical group 0.000 description 10
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 239000007821 HATU Substances 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 238000005191 phase separation Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 3
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 3
- 108091070501 miRNA Proteins 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- JBWYRBLDOOOJEU-UHFFFAOYSA-N 1-[chloro-(4-methoxyphenyl)-phenylmethyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC(OC)=CC=1)C1=CC=CC=C1 JBWYRBLDOOOJEU-UHFFFAOYSA-N 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100154776 Mus musculus Ttr gene Proteins 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- UIZVMOZAXAMASY-UHFFFAOYSA-N hex-5-en-1-ol Chemical compound OCCCCC=C UIZVMOZAXAMASY-UHFFFAOYSA-N 0.000 description 2
- 238000004896 high resolution mass spectrometry Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 2
- 239000011345 viscous material Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- REGGDLIBDASKGE-UHFFFAOYSA-N 12-methoxy-12-oxododecanoic acid Chemical compound COC(=O)CCCCCCCCCCC(O)=O REGGDLIBDASKGE-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- FVMMQJUBNMOPPR-WLDMJGECSA-N N-[(3R,4R,5R,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]formamide Chemical compound OC[C@H]1OC(O)[C@H](NC=O)[C@@H](O)[C@H]1O FVMMQJUBNMOPPR-WLDMJGECSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- LFEYMWCCUAOUKZ-FVGYRXGTSA-N [(2s)-1,5-bis[(2-methylpropan-2-yl)oxy]-1,5-dioxopentan-2-yl]azanium;chloride Chemical compound Cl.CC(C)(C)OC(=O)CC[C@H](N)C(=O)OC(C)(C)C LFEYMWCCUAOUKZ-FVGYRXGTSA-N 0.000 description 1
- FBYFAHNOMBVNGP-UHFFFAOYSA-N acetonitrile;acetyl acetate Chemical compound CC#N.CC(=O)OC(C)=O FBYFAHNOMBVNGP-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004190 ion pair chromatography Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- CZVNLCOJFFYZPG-UHFFFAOYSA-N tert-butyl 4-aminobutanoate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)CCCN CZVNLCOJFFYZPG-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Saccharide Compounds (AREA)
Abstract
本发明属于生物医药技术领域,涉及一种肝靶向化合物、缀合物及应用,所述肝靶向化合物,具有式Ⅰ所示的结构,T为靶向基团,B为分支结构,L1为连接基团,L2为靶向基团和分支结构之间的连接部分,X选自2‑6之间的整数。本发明的肝靶向化合物和缀合物结构明确,将多个半乳糖、半乳糖胺或半乳糖胺衍生物分子链接成三簇或四簇分子,形成分子簇形式,对ASGPR的亲和力明显高于单糖亲和力,能够提高药物肝靶向的递送能力,递送效率高,并维持长效的抑制效果;且合成路线清晰,制备工艺简单。
Description
技术领域
本发明属于生物医药技术领域,尤其涉及一种肝靶向化合物、缀合物及应用。
背景技术
去唾液酸糖蛋白受体(ASGPR)主要表达在肝实质细胞,是肝细胞特异性表达的受体,能够介导去唾液酸化糖蛋白,被肝细胞内吞降解。ASGPR参与糖蛋白、脂质代谢、病毒性肝炎等多种生理功能,对肝部相关疾病的诊断和治疗具有重要的作用。ASGPR能够特异性识别和结合半乳糖、半乳糖胺、N-乙酰半乳糖胺等,因此,含有半乳糖、半乳糖胺及其衍生物的化合物或复合物,能够特异性将药物递送至肝脏,并且高效递送至肝脏细胞。利用靶向肝细胞表面ASGPR受体的半乳糖及其衍生物,实现药物向肝脏的有效递送。利用ASGPR特异性配体在药物向肝细胞递送方面具有广泛的研究和应用。
核酸药物包含核酸适体(Aptamer)、反义核酸(ASO)、小干扰RNA(siRNA)、微小RNA(miRNA)等。核酸药物由于高通用性,能够特异性抑制细胞内的目标基因,在疾病治疗领域具有良好的应用前景。但核酸药物体内递送的挑战一直是限制核酸药物开发的关键。
因此,需要可将小核酸药物高效的递送到肝组织,并维持长效的抑制效果的靶向递送载体。
发明内容
本发明针对上述现有技术存在的不足,提供一种肝靶向化合物、缀合物及应用,具体的技术方案如下:
本发明的第一个目的在于提供一种肝靶向化合物,具有式Ⅰ所示的结构:
T为靶向基团,B为分支结构,L1为连接基团,L2为靶向基团和分支结构之间的连接部分,X选自2-6之间的整数;
其中,L1选自以下基团:
a、c、d、e为0-12之间的整数,b为0-3之间的整数;DMTr为双(4-甲氧基苯基)苯基甲基;
L2选自以下结构的基团:
a1,a2,a3,a4,a5分别为0-12之间的整数,优选为1-8之间的整数。
本发明的肝靶向化合物可将小核酸等药物高效的递送到肝组织,并维持长效的抑制效果。
进一步地,所述B的结构为:
进一步地,所述T靶向基团为半乳糖、半乳糖胺或半乳糖胺衍生物。
进一步地,所述T靶向基团选自半乳糖、半乳糖胺、N-甲酰半乳糖胺、N-乙酰半乳糖胺或N-丙酰半乳糖胺;优选N-乙酰半乳糖胺。
进一步地,所述L1选自以下基团:
进一步地,所述L2选自以下基团:
进一步地,所述X为3或4。
本发明将多个半乳糖、半乳糖胺或半乳糖胺衍生物分子链接成三簇或四簇分子,形成分子簇形式,对ASGPR的亲和力明显高于单糖亲和力,能够提高药物肝靶向的递送能力。
进一步地,所述靶向化合物结构如式H03所示:
进一步地,所述靶向化合物结构如式H05所示:
本发明的第二个目的在于提供一种肝靶向缀合物,由功能基团与上述靶向化合物连接而成。
进一步地,所述肝靶向缀合物还包括其药学上可接受的盐。
进一步地,所述肝靶向缀合物还包括但不限于药学上可接受的赋形剂、稀释剂、缓冲剂或稳定剂。
进一步地,所述功能基团通过磷酸酯基团、硫代磷酸酯基团、膦酸基团、酯键或醚键与连接基团连接。
进一步地,所述功能基团包括小分子药物、多肽、核酸或蛋白等具有生物学功能的活性物质。
进一步地,所述核酸选自小干扰RNA、微小RNA、反义核酸或mRNA片段中的一种或多种。
进一步地,所述核酸为单链寡核苷酸或者双链寡核苷酸。
进一步地,所述连接基团L1连接到核苷酸的末端。
进一步地,所述连接基团L1连接至所述核苷酸的5’末端或连接至所述核苷酸的3’末端。
本发明提供的肝靶向化合物可通过常规的取代反应,酯化反应、酰胺化反应来制备,有多种缩合剂可用于酰胺化反应的制备,可参考文献例如Org.Process Res.Dev.2022,26,1562-1689进行此类化合物的合成。肝靶向缀合物可应用固相合成的方法缀合至核酸序列的3’端,固相合成通过脱保护、偶联、氧化、盖帽工序,循环往复延长核苷酸序列。
本发明第三方面提供一种化合物或缀合物在制备用于诊断、预防、治疗或缓解肝部相关疾病和症状的药物中的应用。
本发明的有益效果为:
本发明的肝靶向化合物和缀合物结构明确,将多个半乳糖、半乳糖胺或半乳糖胺衍生物分子链接成三簇或四簇分子,形成分子簇形式,对ASGPR的亲和力明显高于单糖亲和力,能够提高药物肝靶向的递送能力,递送效率高,并维持长效的抑制效果;且合成路线清晰,制备工艺简单。
附图说明
图1为本发明H03化合物质谱图;
图2为本发明H03化合物H1-NMR核磁谱图;
图3为本发明H05化合物质谱图;
图4为本发明H05化合物H1-NMR核磁谱图;
图5为本发明肝靶向siRNA缀合物小鼠体内TTR mRNA抑制效果图。
具体实施方式
以下结合实例对本发明的原理和特征进行描述,所举实例只用于解释本发明,并非用于限定本发明的范围。
实施例1肝靶向化合物H03的合成
1)化合物2的合成
将化合物1(50.0g,128.4mmol)溶解于300mL无水1,2-二氯乙烷中,在冰水浴且氮气保护条件下,加入三氟甲基磺酸三甲基硅酯(TMSOTf,34.3g,154.3mmol),室温反应过夜。在反应液中加入500mL饱和碳酸氢钠水溶液,搅拌均匀,分出有机相,水相用200mL二氯甲烷萃取3次,合并有机相,依次用200mL饱和碳酸氢钠溶液和200mL饱和氯化钠洗涤1次,分出有机相,无水硫酸钠干燥,减压蒸干溶剂,得到浅黄色粘稠糖稀状粗产品38.3g。该产物不经纯化直接投入下步反应。
2)化合物3的合成
将化合物2(38.0g,115.4mmol)溶于200mL无水1,2-二氯乙烷中,加入5-己烯-1-醇(12.3g,122.8mmol),室温下搅拌30min,然后在冰浴和氮气保护下加入三氟甲基磺酸三甲基硅酯(TMSOTf,12.3g,55.4mmol),室温下搅拌反应过夜。反应液加入200mL二氯甲烷稀释,再加入400mL饱和碳酸氢钠水溶液搅拌10min洗涤,分出有机相;水相用200mL二氯甲烷萃取,有机相依次用200mL饱和碳酸氢钠水溶液和200mL饱和氯化钠洗涤1次,分出有机相用无水硫酸钠干燥,减压蒸干溶剂得到黄色糖稀状产品39.6g。MS m/z[M+H]+(ESI):430.05。
3)化合物4的合成
将化合物3(39.5g,92.0mmol)溶于200mL二氯甲烷和200mL乙腈的混合溶剂中,分别加入270mL去离子水和高碘酸钠(59.0g,275.8mmol),冰水浴下搅拌10min,加入三氯化钌(600mg,2.9mmol),室温反应过夜。反应液加入800mL去离子水搅拌,加饱和碳酸氢钠水溶液调pH约为7.5,分相,水相用500mL二氯甲烷萃取3次,弃去有机相。水相用柠檬酸固体调节pH约为3.0,用500mL二氯甲烷萃取3次,合并有机相,无水硫酸钠干燥,减压蒸干溶剂得到产品9.2g。MS m/z[M+H]+(ESI):448.57。
4)化合物5的合成
将化合物4(3.2g,7.1mmol)溶于32mL二氯甲烷中,加入二异丙基乙胺(2.8g,21.7mmol),2-(7-氮杂苯并三氮唑)-N,N,N’,N’-四甲基脲六氟磷酸酯(HATU,3.3g,8.7mmol),室温下搅拌反应过夜。反应液加入100mL饱和碳酸氢钠水溶液搅拌10min洗涤,分出有机相,水相用100mL二氯甲烷萃取,合并有机相并分别用100mL饱和碳酸氢钠水溶液和100mL饱和氯化钠洗涤,分相,有机相用无水硫酸钠干燥,产物用洗脱液(二氯甲烷:甲醇=2%~20%,V:V)硅胶柱分离,旋干溶剂得到黄色糖稀状产品3.0g。MS m/z[M+H]+(ESI):604.48。
5)化合物6的合成
将化合物5(40.0g,66.3mmol)溶于160mL二氯甲烷中,分批加入80mL盐酸二氧六环溶液(4M),室温下搅拌反应4h。反应液减压蒸干溶剂,得到泡沫状淡橙色固体42.0g。
6)化合物8的合成
将化合物7(2.0g,16.6mmol)溶于50mL二氯甲烷中,加入4,4’-二甲氧基三苯基氯甲烷(DMTrCl,6.8g,20.1mmol),三乙胺(4.0g,39.5mmol),室温下搅拌反应过夜。反应液用50mL饱和氯化钠水洗2次,分相;有机相用无水硫酸钠干燥,减压旋干,得墨绿色粘稠物粗品9.0g。MS m/z[M+H]+(ESI):423.23。
7)化合物9的合成
将化合物8(3.0g,7.1mmol)溶于30mL四氢呋喃中,加入一水合氢氧化锂(LiOH·H2O)的水溶液(0.9g溶于9mL水),室温下搅拌反应过夜。反应液静置分相,有机相用30mL饱和氯化钠洗2次,无水硫酸钠干燥,减压旋干,粗品用80mL甲基叔丁基醚洗涤,过滤,滤饼烘干得淡黄色固体粉末1.5g。
8)化合物10的合成
将化合物9(1.0g,2.4mmol)溶于10mL二氯甲烷中,加入4-氨基丁酸叔丁酯盐酸盐(0.47g,2.4mmol),卡特缩合剂(BOP,1.28g,2.9mmol),三乙胺(0.61g,6.0mmol),室温下搅拌反应过夜。反应液用10mL饱和碳酸氢钠水溶液洗3次,用10mL饱和氯化钠洗1次,分相,有机相用无水硫酸钠干燥,旋干得淡橙黄色半固体1.3g。MS m/z[M+H]+(ESI):550.38。
9)化合物11的合成
将化合物10(1.2g,2.2mmol)溶于18mL四氢呋喃中,加入6mL甲醇,加入一水合氢氧化锂(LiOH·H2O)的水溶液(0.83g溶于12mL水),室温下搅拌反应过夜。反应液减压旋干,加100mL饱和氯化钠,50mL四氢呋喃,分相。水相再次用50mL四氢呋喃萃取2次,合并有机相,用50mL饱和氯化钠洗1次,分相,有机相用无水硫酸钠干燥,旋干得透明粘稠物1.1g。
10)化合物13的合成
将化合物12(10.0g,23.5mmol)溶于100mL二氯甲烷中,加入L-谷氨酸二叔丁酯盐酸盐(7.0g,23.5mmol),二异丙基乙胺(10.6g,81.8mmol),2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU,9.8g,25.8mmol),室温下搅拌反应过夜。反应液用100mL饱和碳酸氢钠水溶液洗3次后,用100mL饱和氯化钠洗1次,分相,有机相用无水硫酸钠干燥,旋干得粘稠物21g。MS m/z[M+H]+(ESI):667.79。
11)化合物14的合成
将化合物13(19.0g,28.5mmol)溶于500mL二氯甲烷中,加入95mL三氟乙酸,室温下搅拌反应4h。反应液减压旋干,加入200mL二氯甲烷打浆2次,过滤,滤饼在45℃烘干,得浅紫色固体11.7g。MS m/z[M+H]+(ESI):499.56。
12)化合物15的合成
将化合物14(3.5g,7.0mmol)溶于120mL N,N-二甲基甲酰胺中,加入化合物6(12.5g,23.2mmol),二异丙基乙胺(9.5g,73.7mmol),2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU,9.6g,25.3mmol),室温下搅拌反应过夜。反应液加800mL饱和氯化钠,再加200mL二氯甲烷萃取2次,合并有机相。有机相用200mL饱和氯化钠洗涤1次,分相,有机相用无水硫酸钠干燥,减压旋干,加入50mL二氯甲烷,50mL甲基叔丁基醚析晶,过滤,滤饼用甲醇复溶,减压蒸干得黄白色固体15.1g。MS m/z[M+H]+(ESI):1955.17。
13)化合物16的合成
将化合物15(10.0g,5.1mmol)溶于100mL N,N-二甲基甲酰胺和40mL四氢呋喃中,加入100mL二异丙基乙胺,置于55℃油浴锅搅拌反应过夜。反应液减压旋干成油状物,乙酸乙酯搅拌回流,静置后倒出上清液,减压旋干,得黄褐色泡沫固体4.0g。MS m/z[M+H]+(ESI):1732.92。
14)化合物17的合成
将化合物16(2.0g,1.15mmol)溶于20mL二氯甲烷中,加入化合物11(0.58g,1.15mmol),二异丙基乙胺(0.37g,2.89mmol),2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU,0.48g,1.27mmol),室温下搅拌反应过夜。反应液加入200mL NaCl溶液,200mL二氯甲烷萃取,分相,有机相减压旋干。加入200mL乙酸乙酯搅拌析晶,过滤,滤饼用甲醇复溶,减压旋干得褐色泡沫状固体1.3g。MS m/z[M+H]+(ESI):2209.31。
15)H03的合成
将化合物17(1.2g,0.54mmol)溶于12mL二氯甲烷中,加入丁二酸酐(544mg,5.43mmol),三乙胺(825mg,8.15mmol),4-二甲氨基吡啶(DMAP,664mg,5.43mmol),室温下搅拌反应过夜。反应液加入200mL二氯甲烷稀释,加200mL NaCl溶液洗1次,用200mL饱和氯化铵水溶液洗2次,用200mL NaCl溶液洗2次。分相,有机相用无水硫酸钠干燥,减压旋干得黄褐色固体粗品840mg。制备液相进行进一步分离纯化,型号Gilson GX281,色谱柱:watersX-bridge C18,19*250mm,10μm。流动相A:碳酸氢铵水溶液,pH=8-9;流动性B:乙腈。流速20ml/min,监测波长214nm,梯度洗脱,冻干后得到淡黄色固体粉末。
H03化合物质谱图如图1所示,H03化合物经高分辨质谱测得分子量为HRMS m/z[M+Na]+(ESI):2331.00,与理论分子量相符。由图2H03化合物H1-NMR核磁谱图可知,检测到目标产物各主要H原子峰和目标产物结构相符。综上,证实该化合物成功合成。
实施例2肝靶向化合物H05的合成
1)化合物20的合成
将化合物19(100g,651mmol)溶于1.3L乙腈,随后在室温下加入三乙胺(161.4g,1595mmol)。然后将三氟乙酸乙酯在25℃水浴下加入,室温下反应24h。反应液过滤,滤液浓缩后,用1L乙酸乙酯洗涤,过滤除去不溶物,滤液用无水硫酸钠干燥,过滤,减压浓缩至恒重,得棕色油状物粗品157g。该产物未经进一步纯化,直接用于后续反应。
2)化合物21的合成
将化合物20(651mmol)溶于1.6L二氯甲烷中,加入三乙胺(98.8g,976mmol),氮气吹扫。在氮气保护下加入DMTrCl(4.269g,12.6mmol)到反应中,室温下反应4h。反应液中加入1.5L饱和氯化钠,搅拌分层,水相再用600mL二氯甲烷萃取2次,合并有机相,减压浓缩至恒重,得棕色油状物粗品384g。该产物未经进一步纯化,直接用于后续反应。
3)化合物22的合成
将化合物21(651mmol)溶于1.8L甲醇中,然后将氢氧化钾水溶液(73.06g,1302mmol溶于430mL去离子水)加入到反应中,室温反应70min。反应液浓缩除去溶剂,加入400mL去离子水洗涤2次,粘性固体用乙酸乙酯溶解,用饱和氯化钠洗涤。旋干得糖稀状物约300g。
4)化合物23的合成
将十二烷二酸单甲酯(7.4g,30.1mmol)置于500mL三口瓶,加入化合物22(12.7g,30.1mmol),加入BOP(16.0g,36.2mmol),加入74mL二氯甲烷搅拌溶解。反应瓶置于常温水浴锅,搅拌下缓慢加入三乙胺(7.6g,75.4mmol),室温搅拌过夜。反应液用80mL饱和碳酸氢钠水溶液洗3次,100mL去离子水洗1次,无水硫酸钠干燥,减压旋干,得橙黄色油状物29.3g。
5)化合物24的合成
将化合物23(29.3g,45.4mmol)置于1L单口瓶,加入300mL四氢呋喃溶解,搅拌下加入一水合氢氧化锂(LiOH·H2O)的水溶液(17.2g,408.3mmol溶于170mL去离子水),室温搅拌过夜。反应液静置分相,上层有机相用170mL饱和氯化钠洗2次,干燥,减压旋干。加260mL二氯甲烷溶解,滴加520mL甲基叔丁基醚,析出固体过滤,烘干,得白色粉末固体18.8g。
6)化合物25的合成
将化合物16(2.0g,1.15mmol)溶于20mL N,N-二甲基甲酰胺中,加入化合物24(729mg,1.15mmol),二异丙基乙胺(0.37g,2.89mmol),2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU,0.48g,1.27mmol),室温下搅拌反应过夜。反应液加300mL饱和氯化钠,200mL二氯甲烷萃取3次,合并有机相,用200mL饱和氯化钠洗1次,分相,有机相干燥,减压旋干,加入200mL乙酸乙酯洗涤,过滤,滤饼甲醇复溶,减压旋干得褐色固体2.1g。
7)H05的合成
将化合物25(2.0g,0.85mmol)溶于40mL二氯甲烷中,加入丁二酸酐(853mg,8.52mmol),三乙胺(1.3g,12.78mmol),4-二甲氨基吡啶(1.0g,8.52mmol),室温下搅拌反应过夜。
反应液加200mL二氯甲烷稀释,加20mL甲醇增加产品溶解度。用200mL氯化钠洗1次,200mL饱和氯化铵水溶液洗2次,200mL氯化钠洗2次。分相,有机相干燥,旋干,得到粗品用甲醇:二氯甲烷:乙酸乙酯(100:10:200,V:V:V)的混合溶液重结晶,过滤。粗品经制备液相进行进一步分离纯化,型号Gilson GX281,色谱柱:waters X-bridge C18,19*250mm,10μm。流动相A:碳酸氢铵水溶液,pH=8-9;流动性B:乙腈。流速20ml/min,监测波长214nm,梯度洗脱,冻干后得到淡黄色固体粉末。
H05化合物质谱图如图3所示,H05化合物经高分辨质谱测得分子量为HRMS m/z[M+Na]+(ESI):2469.10,与理论分子量相符。由图4H05化合物H1-NMR核磁谱图可知,检测到目标产物各主要H原子峰和目标产物结构相符。综上,证实该化合物成功合成。
实施例3siRNA缀合物的制备与活性测试
合成靶向小鼠TTR基因的siRNA,SS链3’末端链接半乳糖分子簇(式Ⅰ-x,x=1~10化合物)。
SS链(5’-3’):asasc agu GuU CUu gcu cua uaa(SEQ ID No.1)
AS链(5’-3’):usUsa uaG agc aag aAc Acu guus usu(SEQ ID No.2)
将化合物H03和H05分别加入适量DMF溶解,再加入2倍当量的苯并三氮唑-N,N,N',N'四甲基脲六氟磷酸盐(HBTU)、N,N-二异丙基乙胺(DIEA,1),加入氨基修饰的固相载体(CPG-NH2),25℃振荡反应24h。反应完成后,依次用乙腈、二氯甲烷洗涤。继续加入20%乙酸酐/80%乙腈,25℃振荡反应24h。反应完成后,依次用乙腈、二氯甲烷洗涤,得到固相载体目标产物H03-CPG,或H05-CPG。
siRNA合成所需核苷单体原料2’-O-甲基等核苷亚磷酰胺单体购自上海兆维科技发展有限公司。3%二氯乙酸作为脱保护剂,0.25M 5-乙硫基-1H-四唑乙腈溶液作为活化剂,N,N-二甲基-N'-(3-硫代-3H-1,2,4-二硫唑-5-基)甲脒的吡啶溶液作为硫化试剂,0.05M碘/吡啶/水溶液作为氧化剂,20%乙酸酐乙腈溶液为盖帽剂A,20%乙腈/N-甲基咪唑/吡啶溶液为盖帽剂B,以上相关合成试剂均购自苏州柯乐玛生物技术有限公司。每条RNA单链采用亚磷酰胺固相合成,以H03-CPG,或H05-CPG为起始,使用DNA合成仪根据合成程序连接核苷亚磷酰胺单体。每个核苷单体连接时包括脱保护、偶联、氧化或硫化、盖帽四步反应。
固相合成完成后,寡核苷酸采用25%-28%氨水在62℃条件下氨解6h。将上清液浓缩蒸干,使用Resource 15Q色谱柱纯化,通过溴化钠溶液梯度洗脱,并使用3%三氟乙酸溶液脱除DMTr,纯化获得寡核苷酸链。收集洗脱液,采用葡聚糖凝胶G25凝胶柱进行脱盐,获得的寡核苷酸链收集后冻干,离子对色谱检测纯度,高分辨质谱分析目标产物分子量。紫外分光光度法定量所得到的单链寡核苷酸,按等摩尔比互补配对,溶于水中,按常规退火方法形成双链siRNA,并调整至实验所需浓度备用。表1为TTR-H03和TTR-H05的SS链和AS链的结构。
表1TTR-H03和TTR-H05的SS链和AS链的结构
备注:小写字母f表示该字母f左侧相邻的一个核苷酸为2’-氟修饰的核苷酸,小写字母a、g、c、u为2’-OMe修饰核苷酸,小写字母s表示与该字母s左右相邻的两个核苷酸之间通过硫代磷酸二酯键连接。
小鼠体内对TTR mRNA表达的抑制
采用8周龄的C57BL/6小鼠(济南朋悦实验动物繁育有限公司,SPF,雌性),随机分组。第0天,在小鼠肩颈部皮肤,给予0.9mg/kg各siRNA缀合物,同时,给予生理盐水作为对照组。分别在0、7、14、21、28天,每组安乐死3只小鼠,取肝脏组织样本。使用实时荧光PCR法检测小鼠肝组织TTR的mRNA表达水平。采用RNAeasy Mini试剂盒(Qiagen,货号74104)提取肝总RNA,根据High Capacity cDNA Reverse Transcription Kits(Thermo Fisher,货号:4368814)逆转录得到cDNA进行RT-PCR。以甘油醛-3-磷酸脱氢酶(GAPDH)基因作为内参基因,按照表1所示RT-PCR方法,分别采用小鼠TTR和GAPDH的Taqman探针引物(表2)检测mRNA表达量。采用2^-ΔΔCt法计算小鼠TTR mRNA表达量,并计算siRNA缀合物TTR-H03和TTR-H05对TTR mRNA的抑制效果。
表2实时荧光定量PCR条件
表3检测引物序列
图5为肝靶向缀合物TTR-H03和TTR-H05对肝脏TTR mRNA的抑制水平,通过对照组归一化后绘制TTRmRNA抑制曲线。如图5所示,siRNA缀合物TTR-H03和TTR-H05均具备将寡核苷酸靶向递送至肝脏的能力,两个化合物均能有效降低肝TTR mRNA水平,并可在长达35天时间里将TTR mRNA表达水平控制在40%以下,其中H05化合物较H03化合物具有更好的递送效率。
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种肝靶向化合物,其特征在于,有式Ⅰ所示的结构:
T为靶向基团,B为分支结构,L1为连接基团,L2为靶向基团和分支结构之间的连接部分,X选自2-6之间的整数;
其中,L1选自以下基团:
a、c、d、e为0-12之间的整数,b为0-3之间的整数;DMTr为双(4-甲氧基苯基)苯基甲基;
L2选自以下结构的基团:
a1,a2,a3,a4,a5分别为0-12之间的整数。
2.根据权利要求1所述的肝靶向化合物,其特征在于,所述B的结构为:
3.根据权利要求1所述的肝靶向化合物,其特征在于,所述T靶向基团为半乳糖、半乳糖胺或半乳糖胺衍生物。
4.根据权利要求1所述的肝靶向化合物,其特征在于,所述L1选自以下基团:
5.根据权利要求1所述的肝靶向化合物,其特征在于,所述L2选自以下基团:
6.根据权利要求1所述的肝靶向化合物,其特征在于,所述靶向化合物结构如式H03所示:
7.根据权利要求1所述的肝靶向化合物,其特征在于,所述靶向化合物结构如式H05所示:
8.一种肝靶向缀合物,其特征在于,由功能基团与如权利要求1-7任一项所述靶向化合物连接而成。
9.根据权利要求8所述的肝靶向化合物,其特征在于,所述功能基团包括小分子药物、多肽、核酸或蛋白。
10.一种如权利要求1-7任一项所述靶向化合物或如权利要求8-9任一项所述靶向缀合物在制备用于诊断、预防、治疗或缓解肝部相关疾病和症状的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311424154.9A CN117466959A (zh) | 2023-10-30 | 2023-10-30 | 一种肝靶向化合物、缀合物及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311424154.9A CN117466959A (zh) | 2023-10-30 | 2023-10-30 | 一种肝靶向化合物、缀合物及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117466959A true CN117466959A (zh) | 2024-01-30 |
Family
ID=89628709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311424154.9A Pending CN117466959A (zh) | 2023-10-30 | 2023-10-30 | 一种肝靶向化合物、缀合物及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117466959A (zh) |
-
2023
- 2023-10-30 CN CN202311424154.9A patent/CN117466959A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109069529B (zh) | 用于治疗性化合物的靶向配体 | |
CN109462981B (zh) | 靶向配体 | |
JP7383308B2 (ja) | 新規化合物及びその適用 | |
KR20230119637A (ko) | 폴리-모르폴리노 올리고뉴클레오티드 갭머 | |
AU2020282453A1 (en) | Nucleic acid, pharmaceutical composition and conjugate, preparation method and use | |
JPH10510822A (ja) | オリゴヌクレオチド−デンドリマー複合体 | |
CN116854754A (zh) | 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物 | |
JP2024508780A (ja) | オリゴヌクレオチドおよび炭水化物をコンジュゲートするための組成物 | |
CN117466959A (zh) | 一种肝靶向化合物、缀合物及应用 | |
CN115920065A (zh) | 一种可靶向去唾液酸糖蛋白受体的配体及其缀合物与用途 | |
EP4396354A1 (en) | Oligonucleotide compositions and methods thereof | |
CN116801886A (zh) | Lpa抑制剂及其用途 | |
CN118302526A (zh) | 一种dsRNA、其制备方法及应用 | |
CN114763547A (zh) | 靶向血管紧张素原的核酸及其用途 | |
CN116903684A (zh) | 一种肝靶向化合物和寡核苷酸缀合物及其应用 | |
CN113292616B (zh) | 一种单糖配体功能化的阳离子脂质类化合物及其制备方法与应用 | |
WO2024140101A1 (zh) | 修饰的双链寡核苷酸分子、修饰的双链寡核苷酸缀合物及其用途 | |
WO2024040531A1 (en) | Novel compositions for conjugating oligonucleotides and carbohydrates | |
WO2023210233A1 (ja) | 糖連結ポリヌクレオチド | |
TW202408490A (zh) | 用於共軛結合寡核苷酸和碳水化合物的新穎组合物 | |
CN116732034A (zh) | 一种抑制agt基因的寡核苷酸或其药学上可接受的盐及应用 | |
TW202408581A (zh) | 用於共軛結合寡核苷酸和碳水化合物的新穎組合物 | |
AU2022349576A1 (en) | Multivalent ligand clusters with diamine scaffold for targeted delivery of therapeutic agents | |
KR20210151593A (ko) | 신규한 몰포리노 올리고뉴클레오티드 유도체 | |
WO2024023267A2 (en) | Nucleic acid compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |